Kamada Ltd (NASDAQ:KMDA)., a pharmaceutical company specializing in plasma-derived protein therapeutics, has announced a significant contract for the supply of its products in Latin America. The agreement, valued at $25 million, is set to last three years and involves the provision of KAMRAB® and VARIZIG® to undisclosed parties within the region.
According to InvestingPro data, Kamada maintains excellent financial health with a "GREAT" overall score, supported by strong liquidity metrics and a healthy balance sheet showing minimal debt-to-equity of just 0.04.
KAMRAB® is Kamada’s rabies immune globulin, which is used for post-exposure prophylaxis, while VARIZIG® is a varicella-zoster immune globulin for post-exposure treatment of varicella. Both products are critical in preventing the development of diseases after exposure to the respective viruses. The company has demonstrated solid operational performance, generating $158.38 million in revenue over the last twelve months, with a healthy gross profit margin of 42.5%.
The announcement, made public through a Form 6-K filing with the U.S. Securities and Exchange Commission today, indicates Kamada’s commitment to expanding its global reach and underscores the demand for its specialized pharmaceutical products.
Kamada’s Vice President General Counsel and Corporate Secretary, Nir Livneh, signed off on the report, ensuring the accuracy and authorization of the information provided.
While the details of the parties involved in the Latin American contract remain confidential, this development marks a significant step for Kamada in the international healthcare market. The company’s ability to secure such a contract reflects its position within the pharmaceutical preparations industry, particularly in the field of immune globulin products.
Investors and stakeholders in Kamada Ltd., which is listed on the NASDAQ under the ticker KMDA, may view this contract as a positive indicator of the company’s business prospects and operational growth.
This report is based on a press release statement filed by Kamada Ltd. with the SEC and does not include any additional commentary or speculative statements.
In other recent news, Kamada Ltd. reported a 10% increase in total revenues for Q3, hitting $41.7 million, and an 11% rise in adjusted EBITDA to $8.8 million. For the first nine months of the year, the company saw a 15% revenue increase to $121.9 million and a 43% surge in adjusted EBITDA to $25.4 million.
These recent developments prompted Kamada to raise its full-year adjusted EBITDA forecast to between $32 million and $35 million, while maintaining its revenue guidance at $158 million to $162 million.
Kamada’s growth strategy includes organic growth from FDA-approved products, business development, and plasma collection expansion. The company has already opened a new plasma collection center in Houston and plans to open another in San Antonio in H1 2025.
Analysts noted the company’s KEDRAB and CYTOGAM products are experiencing significant double-digit growth, solidifying Kamada’s position as a global leader in anti-rabies immune globulin with a market share between 40% and 50%. Kamada is also actively pursuing business development opportunities with an expected commercial impact by 2025.
Finally, Kamada’s operational cash flow remains robust at $37.2 million, and with $72 million in cash reserves at the end of Q3, the company is well-positioned to support its growth initiatives and explore potential mergers and acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.